Risk and impact of herpes zoster on patients with diabetes: A population-based study, 2009–2014

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 11, 2017, Pages 2606-2611

  Muñoz Quiles, Cintia ^a   López Lacort, Mónica ^a   Ampudia Blasco, F Javier ^b   Díez Domingo, Javier ^a,c  

^a Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

Author keywords

diabetes; epidemiology; healthcare resources consumption; herpes zoster; impact; population based study; vaccine

Indexed keywords

CORTICOSTEROID; HEMOGLOBIN A1C;

ADULT; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; GENDER; GLYCEMIC CONTROL; HERPES ZOSTER; HUMAN; ICD-9; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; POPULATION RESEARCH; RETROSPECTIVE STUDY; DIABETIC COMPLICATION; FACTUAL DATABASE; HEALTH SURVEY; ISOLATION AND PURIFICATION; POSTHERPETIC NEURALGIA; RISK FACTOR; SPAIN; VACCINATION; VARICELLA ZOSTER VIRUS; VERY ELDERLY; VIROLOGY;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; VACCINATION;

EID: 85034780728     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1368600     Document Type: Article

References (32)

1. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: A prospective study. CMAJ. 2010;182(16):1731-1736. https://doi.org/10.1503/cmaj.091711. PMID:20921251
2. Arvin AM. Humoral and cellular immunity to varicella-zoster virus: An overview. J Infect Dis. 2008;197:S58-S60. https://doi.org/10.1086/522123. PMID:18419410
3. Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews. 2014;(2). https://doi.org/10.1002/14651858.CD006866.pub3
4. Johnson RW, Rice ASC. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526-1533. https://doi.org/10.1056/NEJMcp1403062. PMID:25317872
5. Gater A, Uhart M, McCool R, Preaud E. The humanistic, economic and societal burden of herpes zoster in europe: A critical review. BMC Public Health. 2015;15:1514-1514. https://doi.org/10.1186/s12889-015-1514-y]
6. Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481-1486. https://doi.org/10.1086/320169. PMID:11317250
7. Morant-Talamante N, Diez-Domingo J, Martinez-Ubeda S, Puig-Barbera J, Aleman-Sanchez S, Perez-Breva L. Herpes zoster surveillance using electronic databases in the valencian community (spain). BMC Infect Dis. 2013;13:463.
8. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284. https://doi.org/10.1056/NEJMoa051016. PMID:15930418
9. Harpaz R. Ortega-Sanchez IR, Seward JF, Advisory committee on immunization practices centers for D, Control and P. Prevention of herpes zoster: Recommendations of the advisory committee on immunization practices (acip). MMWR. Recomm Rep: Morb Mortal Wkly Rep. Recomm Reps / CDC. 2008;57(RR-5):1-30; quiz CE32-34.
10. Oxman MN, Levin MJ, Group SPS. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197 Suppl 2:S228-236. https://doi.org/10.1086/522159]
11. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14. https://doi.org/10.1016/j.diabres.2009.10.007. PMID:19896746
12. Peleg AY, Weerarathna T, McCarthy JS, Davis TME. Common infections in diabetes: Pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23(1):3-13. https://doi.org/10.1002/dmrr.682. PMID:16960917
13. Geerlings SE, Hoepelman AIM. Immune dysfunction in patients with diabetes mellitus (dm). FEMS Immunol Med Microbiol. 1999;26(3-4):259-265.
14. Guignard AP, Greenberg M, Lu C, Rosillon D, Vannappagari V. Risk of herpes zoster among diabetics: A matched cohort study in a us insurance claim database before introduction of vaccination, 1997–2006. Infection. 2014;42(4):729-735.
15. Suaya JA, Chen S-Y, Li Q, Burstin SJ, Levin MJ. Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the united states. Open Forum Infect Dis. 2014;1(2):ofu049.[https://doi.org/10.1093/ofid/ofu049. PMID:25734121
16. Aldaz P, Diaz JA, Loayssa JR, Dronda MJ, Oscariz M, Castilla J. Herpes zoster incidence in diabetic patients. An Sist Sanit Navar. 2013;36(1):57-62. https://doi.org/10.4321/S1137-66272013000100006. PMID:23648493
17. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, Kokia E, Shalev V. Diabetes as a risk factor for herpes zoster infection: Results of a population-based study in israel. Infection. 2008;36(3):226-230. https://doi.org/10.1007/s15010-007-6347-x. PMID:18454342
18. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: Population based case-control study. BMJ. 2014;348:g2911.[https://doi.org/10.1136/bmj.g2911. PMID:25134101
19. Ragozzino MW, Melton LJ, Kurland LT. Herpes-zoster and diabetes-mellitus–an epidemiological investigation. J Chronic Dis. 1983;36(7):501-505. https://doi.org/10.1016/0021-9681(83)90127-3. PMID:6874881
20. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes-zoster. Arch Intern Med. 1995;155(15):1605-1609.
21. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, Fraser VJ, Cunningham F, Eisen SA. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(10):1364-1371. https://doi.org/10.1086/598331. PMID:19368499
22. Lasserre A, Blaizeau F, Gorwood P, Bloch K, Chauvin P, Liard F, Blanchon T, Hanslik T. Herpes zoster: Family history and psychological stress-case-control study. J Clin Virol. 2012;55(2):153-157. https://doi.org/10.1016/j.jcv.2012.06.020. PMID:22824229
23. Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis. 2009;200(10):1606-1610. https://doi.org/10.1086/644646. PMID:19821719
24. Instituto nacional de estadística. Cifras oficiales de población resultantes de la revisión del padrón municipal a 1 de enero de 2014. 2014. [accessed]. http://www.ine.es/dynt3/inebase/es/index.html?padre=517&dh=1.
25. Indra sistemas sa: Proyecto abucasis conselleria sanitat valencia. 2012. [accessed]. http://www.indracompany.com/sectores/sanidad/proyectos/179/proyecto-abucasis-conselleria-de-sanitat-valencia.
26. Munoz-Quiles C, Lopez-Lacort M, Ubeda-Sansano I, Aleman-Sanchez S, Perez-Vilar S, Puig-Barbera J, Diez-Domingo J. Population-based analysis of bronchiolitis epidemiology in valencia, spain. Pediatr Infect Dis J. 2016;35(3):275-280. https://doi.org/10.1097/INF.0000000000000993. PMID:26658376
27. Weitzman D, Shavit O, Stein M, Cohen R, Chodick G, Shalev V. A population based study of the epidemiology of herpes zoster and its complications. J Infect. 2013;67(5):463-469. https://doi.org/10.1016/j.jinf.2013.06.016. PMID:23872209
28. Chen H-H, Lin IC, Chen H-J, Yeh S-Y, Kao C-H. Association of herpes zoster and type 1 diabetes mellitus. Plos One. 2016;11(5):e0155175. https://doi:10.1371/journal.pone.0155175
29. Li Q, Ali MA, Cohen JI. Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell. 2006;127(2):305-316. https://doi.org/10.1016/j.cell.2006.08.046. PMID:17055432
30. Cebrian-Cuenca AM, Diez-Domingo J, San-Martin-Rodriguez M, Puig-Barbera J, Navarro-Perez J, Herpes Zoster Res Grp V. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the valencian community of spain. BMC Infect Dis. 2011;11:302. https://doi.org/10.1186/1471-2334-11-302
31. Luis Lopez-Belmonte J, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M. The use of zostavax in spain: The economic case for vaccination of individuals aged 50 years and older. J Med Econ. 2016;19(6):576-586. https://doi.org/10.3111/13696998.2016.1146726. PMID:26808422
32. Pérez-Vilar S, Díez-Domingo J, Puig-Barberá J, Gil-Prieto R, Romio S. Intussusception following rotavirus vaccination in the valencia region, spain. Hum Vaccin Immunother. 2015;11(7):1848–52. https://doi.org/10.1080/21645515.2015.1049787. PMID:26083707